Artificial intelligence for dementia research methods optimization

Artificial intelligence (AI) and machine learning (ML) approaches are increasingly being used in dementia research. However, several methodological challenges exist that may limit the insights we can obtain from high-dimensional data and our ability to translate these findings into improved patient outcomes. To improve reproducibility and replicability, researchers should make their well-documented code and modeling pipelines openly available. Data should also be shared where appropriate. To enhance the acceptability of models and AI-enabled systems to users, researchers should prioritize interpretable methods that provide insights into how decisions are generated. Models should be developed using multiple, diverse datasets to improve robustness, generalizability, and reduce potentially harmful bias. To improve clarity and reproducibility, researchers should adhere to reporting guidelines that are co-produced with multiple stakeholders. If these methodological challenges are overcome, AI and ML hold enormous promise for changing the landscape of dementia research and care. HIGHLIGHTS: Machine learning (ML) can improve diagnosis, prevention, and management of dementia. Inadequate reporting of ML procedures affects reproduction/replication of results. ML models built on unrepresentative datasets do not generalize to new datasets. Obligatory metrics for certain model structures and use cases have not been defined. Interpretability and trust in ML predictions are barriers to clinical translation

Predictive analytics applied to Alzheimer’s disease : a data visualisation framework for understanding current research and future challenges

Dissertation as a partial requirement for obtaining a master’s degree in information management, with a specialisation in Business Intelligence and Knowledge Management.Big Data is, nowadays, regarded as a tool for improving the healthcare sector in many areas, such as in its economic side, by trying to search for operational efficiency gaps, and in personalised treatment, by selecting the best drug for the patient, for instance. Data science can play a key role in identifying diseases in an early stage, or even when there are no signs of it, track its progress, quickly identify the efficacy of treatments and suggest alternative ones. Therefore, the prevention side of healthcare can be enhanced with the usage of state-of-the-art predictive big data analytics and machine learning methods, integrating the available, complex, heterogeneous, yet sparse, data from multiple sources, towards a better disease and pathology patterns identification. It can be applied for the diagnostic challenging neurodegenerative disorders; the identification of the patterns that trigger those disorders can make possible to identify more risk factors, biomarkers, in every human being. With that, we can improve the effectiveness of the medical interventions, helping people to stay healthy and active for a longer period. In this work, a review of the state of science about predictive big data analytics is done, concerning its application to Alzheimer’s Disease early diagnosis. It is done by searching and summarising the scientific articles published in respectable online sources, putting together all the information that is spread out in the world wide web, with the goal of enhancing knowledge management and collaboration practices about the topic. Furthermore, an interactive data visualisation tool to better manage and identify the scientific articles is develop, delivering, in this way, a holistic visual overview of the developments done in the important field of Alzheimer’s Disease diagnosis.Big Data é hoje considerada uma ferramenta para melhorar o sector da saúde em muitas áreas, tais como na sua vertente mais económica, tentando encontrar lacunas de eficiência operacional, e no tratamento personalizado, selecionando o melhor medicamento para o paciente, por exemplo. A ciência de dados pode desempenhar um papel fundamental na identificação de doenças em um estágio inicial, ou mesmo quando não há sinais dela, acompanhar o seu progresso, identificar rapidamente a eficácia dos tratamentos indicados ao paciente e sugerir alternativas. Portanto, o lado preventivo dos cuidados de saúde pode ser bastante melhorado com o uso de métodos avançados de análise preditiva com big data e de machine learning, integrando os dados disponíveis, geralmente complexos, heterogéneos e esparsos provenientes de múltiplas fontes, para uma melhor identificação de padrões patológicos e da doença. Estes métodos podem ser aplicados nas doenças neurodegenerativas que ainda são um grande desafio no seu diagnóstico; a identificação dos padrões que desencadeiam esses distúrbios pode possibilitar a identificação de mais fatores de risco, biomarcadores, em todo e qualquer ser humano. Com isso, podemos melhorar a eficácia das intervenções médicas, ajudando as pessoas a permanecerem saudáveis e ativas por um período mais longo. Neste trabalho, é feita uma revisão do estado da arte sobre a análise preditiva com big data, no que diz respeito à sua aplicação ao diagnóstico precoce da Doença de Alzheimer. Isto foi realizado através da pesquisa exaustiva e resumo de um grande número de artigos científicos publicados em fontes online de referência na área, reunindo a informação que está amplamente espalhada na world wide web, com o objetivo de aprimorar a gestão do conhecimento e as práticas de colaboração sobre o tema. Além disso, uma ferramenta interativa de visualização de dados para melhor gerir e identificar os artigos científicos foi desenvolvida, fornecendo, desta forma, uma visão holística dos avanços científico feitos no importante campo do diagnóstico da Doença de Alzheimer

An MRI-Derived Definition of MCI-to-AD Conversion for Long-Term, Automati c Prognosis of MCI Patients

Alzheimer's disease (AD) and mild cognitive impairment (MCI), continue to be widely studied. While there is no consensus on whether MCIs actually "convert" to AD, the more important question is not whether MCIs convert, but what is the best such definition. We focus on automatic prognostication, nominally using only a baseline image brain scan, of whether an MCI individual will convert to AD within a multi-year period following the initial clinical visit. This is in fact not a traditional supervised learning problem since, in ADNI, there are no definitive labeled examples of MCI conversion. Prior works have defined MCI subclasses based on whether or not clinical/cognitive scores such as CDR significantly change from baseline. There are concerns with these definitions, however, since e.g. most MCIs (and ADs) do not change from a baseline CDR=0.5, even while physiological changes may be occurring. These works ignore rich phenotypical information in an MCI patient's brain scan and labeled AD and Control examples, in defining conversion. We propose an innovative conversion definition, wherein an MCI patient is declared to be a converter if any of the patient's brain scans (at follow-up visits) are classified "AD" by an (accurately-designed) Control-AD classifier. This novel definition bootstraps the design of a second classifier, specifically trained to predict whether or not MCIs will convert. This second classifier thus predicts whether an AD-Control classifier will predict that a patient has AD. Our results demonstrate this new definition leads not only to much higher prognostic accuracy than by-CDR conversion, but also to subpopulations much more consistent with known AD brain region biomarkers. We also identify key prognostic region biomarkers, essential for accurately discriminating the converter and nonconverter groups

딥러닝 기반 군집화 방법을 이용하여 FDG PET에서 알츠하이머병의 공간적 뇌 대사 패턴의 특징적 아형 분류

학위논문(박사) -- 서울대학교대학원 : 융합과학기술대학원 분자의학 및 바이오제약학과, 2022.2. 이동수.알츠하이머병은 아밀로이드와 타우 침착과 같은 병리학적 특징을 공유함에도 불구하고 광범위한 임상병리학적 특성을 보인다. 본 연구에서는 딥러닝 기반 군집화 방법을 이용하여 FDG PET 영상에서 알츠하이머병 특징적 아형을 분류하여 신경 퇴행의 공간적 뇌 대사 패턴을 이해하고자 하였으며, 공간적 뇌 대사 패턴에 의해 정의된 아형의 임상병리학적 특징을 밝히고자 하였다. Alzheimer’s Disease Neuroimaging Initiative(ADNI) 데이터베이스로부터 첫번째 방문 및 추적 방문을 포함한 알츠하이머병, 경도인지장애, 인지 정상군의 총 3620개의 FDG 뇌 양전자단층촬영(PET) 영상을 수집하였다. 알츠하이머병에서 질병의 진행 외의 뇌 대사 패턴을 나타내는 표현(representation)을 찾기 위하여, 조건부 변이형 오토인코더(conditional variational autoencoder)를 사용하였으며, 인코딩된 표현으로부터 군집화(clustering)를 시행하였다. 알츠하이머병의 뇌 FDG PET (n=838)과 CDR-SB(Clinical Demetria Rating Scale Sum of Boxes) 점수가 cVAE 모델의 입력값으로 사용되었으며, 군집화에는 k-means 알고리즘이 사용되었다. 훈련된 딥러닝 모델은 경도인지장애군 (n=1761)의 뇌 FDG PET에 전이(transfer)되어 각 아형의 서로 다른 궤적(trajectory)과 예후를 밝히고자 하였다. 통계적 파라미터 지도작성법(Statistical Parametric Mapping, SPM)을 이용하여 각 군집의 공간적 패턴을 시각화 하였으며, 각 군집의 임상적 및 생물학적 특징을 비교하였다. 또한 아형 별 경도인지장애로부터 알츠하이머병으로 전환되는 비율을 비교하였다. 딥러닝 기반 군집화 방법으로 4개의 특징적 아형이 분류되었다. (i) S1 (angular): 모이랑(angular gyrus)에서 현저한 대사 저하를 보이며 분산된 피질의 대사 저하 패턴, 남성에서 빈도 높음, 더 많은 아밀로이드 침착, 더 적은 타우 침착, 더 심한 해마 위축, 초기 단계의 인지 저하의 특징을 보였다. (ii) S2 (occipital): 후두엽(occipital) 피질에서 현저한 대사 저하를 보이며 후부 우세한 대사 저하 패턴, 더 적은 연령, 더 많은 타우, 더 적은 해마 위축, 더 낮은 집행 및 시공간 점수, 경도인지장애로부터 알츠하이머병으로의 빠른 전환의 특징을 보였다. (iii) S3(orbitofrontal): 안와전두(orbitofrontal) 피질에서 현저한 대사 저하를 보이며 전방 우세한 대사 저하 패턴, 더 높은 연령, 더 적은 아밀로이드 침착, 더 심한 해마 위축, 더 높은 집행 및 시공간 점수의 특징을 보였다. (iv) S4(minimal): 최소의 대사 저하를 보임, 여성에서 빈도 높음, 더 적은 아밀로이드 침착, 더 많은 타우 침착, 더 적은 해마 위축, 더 높은 인지기능 점수의 특징을 보였다. 결론적으로, 본 연구에서 우리는 서로 다른 뇌 병리 및 임상 특성을 가진 알츠하이머병의 특징적 아형을 분류하였다. 또한 우리 딥러닝 모델은 경도인지장애군에 성공적으로 전이되어 아형 별 경도인지장애로부터 알츠하이머병으로 전환되는 예후를 예측할 수 있었다. 본 결과는 FDG PET에서 알츠하이머병의 특징적 아형은 개인의 임상 결과에 영향을 미칠 수 있고, 병태생리학 측면에서 알츠하이머병의 광범위한 스펙트럼을 이해하는데 단서를 제공할 수 있음을 시사한다.Alzheimer’s disease (AD) presents a broad spectrum of clinicopathologic profiles, despite common pathologic features including amyloid and tau deposition. Here, we aimed to identify AD subtypes using deep learning-based clustering on FDG PET images to understand distinct spatial patterns of neurodegeneration. We also aimed to investigate clinicopathologic features of subtypes defined by spatial brain metabolism patterns. A total of 3620 FDG brain PET images with AD, mild cognitive impairment (MCI), and cognitively normal controls (CN) at baseline and follow-up visits were obtained from Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. In order to identify representations of brain metabolism patterns different from disease progression in AD, a conditional variational autoencoder (cVAE) was used, followed by clustering using the encoded representations. FDG brain PET images with AD (n=838) and Clinical Demetria Rating Scale Sum of Boxes (CDR-SB) scores were used as inputs of cVAE model and the k-means algorithm was applied for the clustering. The trained deep learning model was also transferred to FDG brain PET image with MCI (n=1761) to identify differential trajectories and prognosis of subtypes. Statistical parametric maps were generated to visualize spatial patterns of clusters, and clinical and biological characteristics were compared among the clusters. The conversion rate from MCI to AD was also compared among the subtypes. Four distinct subtypes were identified by deep learning-based FDG PET clusters: (i) S1 (angular), showing prominent hypometabolism in the angular gyrus with a diffuse cortical hypometabolism pattern; frequent in males; more amyloid; less tau; more hippocampal atrophy; cognitive decline in the earlier stage. (ii) S2 (occipital), showing prominent hypometabolism in the occipital cortex with a posterior-predominant hypometabolism pattern; younger age; more tau; less hippocampal atrophy; lower executive and visuospatial scores; faster conversion from MCI to AD. (iii) S3 (orbitofrontal), showing prominent hypometabolism in the orbitofrontal cortex with an anterior-predominant hypometabolism pattern; older age; less amyloid; more hippocampal atrophy; higher executive and visuospatial scores. (iv) S4 (minimal), showing minimal hypometabolism; frequent in females; less amyloid; more tau; less hippocampal atrophy; higher cognitive scores. In conclusion, we could identify distinct subtypes in AD with different brain pathologies and clinical profiles. Also, our deep learning model was successfully transferred to MCI to predict the prognosis of subtypes for conversion from MCI to AD. Our results suggest that distinct AD subtypes on FDG PET may have implications for the individual clinical outcomes and provide a clue to understanding a broad spectrum of AD in terms of pathophysiology.1. Introduction 1 1.1 Heterogeneity of Alzheimer's disease 1 1.2 FDG PET as a biomarker of Alzheimer's disease 1 1.3 Biologic subtypes of Alzheimer's disease 2 1.4 Dimensionality reduction methods 5 1.5 Variational autoencoder for clustering 8 1.6 Final goal of the study 10 2. Methods 11 2.1 Subjects 11 2.2 FDG PET data acquisition and preprocessing 12 2.3 Deep learning-based model for representations of FDG PET in AD 12 2.4 Clustering method for AD subtypes on FDG PET 17 2.5 Transfer of deep learning-based FDG PET cluster model for MCI subtypes 17 2.6 Visualization of subtype-specific spatial brain metabolism pattern 21 2.7 Clinical and biological characterization 21 2.8 Prognosis prediction of MCI subtypes 22 2.9 Generation of subtype-specific FDG PET images 22 2.10 Statistical analysis 23 3. Results 24 3.1 Deep learning-based FDG PET clusters 24 3.2 Spatial brain metabolism pattern in AD subtypes 27 3.3 Clinical and biological characterization in AD subtypes 32 3.4 Subtype-specific spatial metabolism patterns resemble in MCI 43 3.5 Clinical and biological characterization in MCI subtypes 50 3.6 Prognosis prediction of subtypes for conversion from MCI to AD 56 3.7 Generating FDG PET images of AD subtypes 61 4. Discussion 66 4.1 Limitations of previous subtyping approach 68 4.2 Interpretation of results 68 4.3 Strength of our deep learning-based clustering approach 73 4.4 Strength of our deep learning-based AD subtypes 77 4.5 Limitations and future directions 82 5. Conclusion 83 References 84 Supplementary Figures 99 국문 초록 101박

Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: a systematic review

Introduction: Artificial intelligence (AI) and neuroimaging offer new opportunities for diagnosis and prognosis of dementia. Methods: We systematically reviewed studies reporting AI for neuroimaging in diagnosis and/or prognosis of cognitive neurodegenerative diseases. Results: A total of 255 studies were identified. Most studies relied on the Alzheimer's Disease Neuroimaging Initiative dataset. Algorithmic classifiers were the most commonly used AI method (48%) and discriminative models performed best for differentiating Alzheimer's disease from controls. The accuracy of algorithms varied with the patient cohort, imaging modalities, and stratifiers used. Few studies performed validation in an independent cohort. Discussion: The literature has several methodological limitations including lack of sufficient algorithm development descriptions and standard definitions. We make recommendations to improve model validation including addressing key clinical questions, providing sufficient description of AI methods and validating findings in independent datasets. Collaborative approaches between experts in AI and medicine will help achieve the promising potential of AI tools in practice. Highlights: There has been a rapid expansion in the use of machine learning for diagnosis and prognosis in neurodegenerative disease Most studies (71%) relied on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset with no other individual dataset used more than five times There has been a recent rise in the use of more complex discriminative models (e.g., neural networks) that performed better than other classifiers for classification of AD vs healthy controls We make recommendations to address methodological considerations, addressing key clinical questions, and validation We also make recommendations for the field more broadly to standardize outcome measures, address gaps in the literature, and monitor sources of bias